Journal of Mid-life Health Journal of Mid-life Health
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission | Subscribe | Advertise Users Online: 298  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 

 Table of Contents 
Year : 2022  |  Volume : 13  |  Issue : 3  |  Page : 241-243  

Epithelioid leiomyosarcoma of the uterus and the diagnostic challenge in diagnosing it on small biopsy

Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India

Date of Submission03-Feb-2022
Date of Decision26-Sep-2022
Date of Acceptance27-Sep-2022
Date of Web Publication14-Jan-2023

Correspondence Address:
Durre Aden
Department of Pathology, 4th Floor, College Building, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi - 110 029
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jmh.jmh_36_22

Rights and Permissions

Epithelioid leiomyosarcoma of the uterus is a rare soft-tissue tumor of the pelvis with <1% cases. It can be asymptomatic or can reach an enormous size, resulting in chronic pelvic pain, postmenopausal bleeding, or may cause bowel and bladder dysfunction. The diagnostic dilemma arises especially when they have epithelioid morphology. This case is being presented because of its rare incidence along with the diagnostic dilemma it presented due to epithelioid morphology which is a very rare presentation, especially challenging on small biopsies. This case also highlights the usefulness of immunohistochemical markers, such as WT1, p53, and p16, which has important diagnostic as well as prognostic values in rare variants of usual tumors. Leiomyosarcoma per se is a highly aggressive tumor, therefore, timely diagnosis and management are advised.

Keywords: Epithelioid leiomyosarcoma, neoplasm, pelvis, uterus

How to cite this article:
Aden D, Zaheer S, Singh S, Ranga S. Epithelioid leiomyosarcoma of the uterus and the diagnostic challenge in diagnosing it on small biopsy. J Mid-life Health 2022;13:241-3

How to cite this URL:
Aden D, Zaheer S, Singh S, Ranga S. Epithelioid leiomyosarcoma of the uterus and the diagnostic challenge in diagnosing it on small biopsy. J Mid-life Health [serial online] 2022 [cited 2023 Jan 26];13:241-3. Available from:

   Introduction Top

Leiomyosarcoma of the uterus is a rare soft-tissue tumor of the female pelvis with <1% of uterine tumor.[1] It usually arises from the uterine myometrium de novo or is very rarely transformed from a preexisting benign leiomyoma. These tumors are found mainly in females 40–60 years of age.[2] Leiomyomas are commonly seen in the reproductive age group, and a strong suspicion of leiomyosarcoma should be kept in mind in cases of fibroid with postmenopausal bleeding.[3] The World Health Organization classification of tumors of female genital organs classifies leiomyosarcoma into three types – conventional (spindle cell), epithelioid, and myxoid variant. Conventional leiomyosarcoma is the most common one. Myxoid and epithelioid variants of leiomyosarcoma are rare.[4] World Health Organization classification of female genital tract tumors in the latest 5th edition recommends a diagnosis of epithelioid leiomyosarcoma if there are >50% cells showing epithelioid morphology with tumor cells showing moderate-to-severe atypia along with tumor cell necrosis or ≥1.6 mitoses/mm2.[2] There are very few cases of epithelioid leiomyosarcoma reported in the past. This case is being reported because of its diagnostic challenge apart from its rarity.[5] To the best of our knowledge, ours is the first case of lymph node metastasis of epithelioid leiomyosarcoma. It also highlights the need for complimentary newer IHCs such as p53, p16, and WT1 which are helpful in the diagnosis and they have a prognostic significance also.

   Case Report Top

A 46-year-old postmenopausal female presented to the gynecology outpatient department at our hospital with symptoms of postmenopausal bleeding for the past 3 months along with abdominal obstruction. There was a history of significant weight loss and loss of appetite. There were no bladder or bowel complaints. Ultrasound abdomen revealed multiple ill-defined hypodense lesions in the anterior and posterior myometrium. Contrast-enhanced computed tomography abdomen–pelvis showed a large solid cystic mass of 7.2 cm × 9.5 cm × 7.6 cm with significant contrast enhancement in the posterior uterine wall suggestive of a sarcomatoid change in leiomyoma [Figure 1]. The rest of the uterus and adnexa appeared normal. There were multiple heterogeneous enhancing lesions in bilateral common and internal iliac and other mesenteric lymph nodes (metastatic).
Figure 1: Contrast-enhanced axial CT image shows heterogeneously enhancing solid and cystic areas in the pelvis. CT: Computed tomography

Click here to view

On abdominal examination, a large, nontender, solid, mobile abdominopelvic mass of 22 weeks gravid uterus size was felt. On per speculum examination, the cervix could be visualized, and no abnormal discharge was seen. On vaginal examination, a nontender mass was felt. Routine blood analysis was within normal limits. An explorative laparotomy was performed and it was found that the tumor was arising from the uterus with normal bilateral fallopian tubes and ovaries lying separately from the mass. The biopsy from the lesion was sent for histopathological examination. H and E sections revealed a tumor mass composed of round to spindle to epithelioid cells in sheets and nests separated by delicate vasculature. The tumor cells had eosinophilic to granular cytoplasm, irregular nuclear contour, and granular to vesicular chromatin with variably prominent nucleoli. Abnormal mitotic figures and necrosis were present [Figure 2]. On immunohistochemistry, the tumor cells were positive for estrogen receptor (ER), progesterone receptor (PR), vimentin, cytokeratin, WT1, p53, and a very high Ki67 labeling index. They were negative for smooth muscle actin (SMA), desmin, CD117, CK7, CK20, HMWCK, MyoD1, S100, p16, and HMB45. Therefore, a histological diagnosis of an epithelioid leiomyosarcoma was made [Figure 3].
Figure 2: Microphotographs of the tumor show tumor cells with polygonal or round cells with eosinophilic cytoplasm and round-to-ovoid nuclei (H and E, ×100) (a and b)

Click here to view
Figure 3: Tumor cells are positive for ER (a), PR (b), vimentin (c) WT1 (d). ER: Estrogen receptor, PR: Progesterone receptor

Click here to view

   Discussion Top

According to the 2020 WHO classification, uterine sarcoma consists of leiomyosarcoma, low- and high-grade endometrial stromal sarcoma, and undifferentiated sarcoma.[2] Epithelioid leiomyosarcomas have very rarely been reported in the literature and can be very unpredictable.[6] They can remain dormant for long periods or recur after years. The most frequent presenting symptoms are abnormal vaginal bleeding and pelvic or abdominal pain. Two rare variants of leiomyosarcomas, epithelioid and myxoid leiomyosarcoma, can be difficult to diagnose, as their pathologic and diagnostic features are different from those of usual spindle cell leiomyosarcomas.[7] The diagnosis of epithelioid leiomyosarcoma requires the presence of predominantly epithelioid morphology with a round-to-polygonal cell with eosinophilic cytoplasm and round-to-ovoid nuclei comprising most (≥50%) of the tumor cells. In both these subtypes of leiomyosarcomas, nuclear atypia is mild and the mitotic rate is usually <3 mitotic figures/10 HPF. Further, in myxoid leiomyosarcomas, cellularity is usually low and in epithelioid leiomyosarcoma is very scant or absent. Hence, a differential diagnosis has to be made, also with a variety of benign smooth muscle tumors that exhibit atypical histologic features and unusual growth patterns.

The differential diagnosis of epithelioid leiomyosarcoma includes entities with epithelioid and round cell morphology. This includes perivascular epithelioid cell tumor (PEComa), uterine tumor resembling ovarian sex cord-stromal tumor (UTROSCT), rhabdomyosarcoma, and another undifferentiated uterine sarcoma. PEComa is a challenging mimicker. It is excluded if there is the presence of clear epithelioid cells which is rare and focally present in PEComa with the presence of expression of melanocytic markers. UTROSCT is positive for smooth muscle markers, expression of ovarian sex cord-stromal markers, and keratins. Sex cord-like morphology can occur in epithelioid leiomyosarcoma but sex cord-like areas should be positive for desmin, SMA, and WT1, but negative for inhibin, calretinin, and CD10, suggesting morphologic mimicry rather than true sex cord-stromal differentiation. ER and PR positivity show the highly variable result in cases of leiomyosarcoma, unlike the leiomyoma uterus. WT1 is a transcription factor needed for the development of the genitourinary tract and is seen in both uterine and soft-tissue LMS. The presence of WT1 shows an adverse prognostic indicator in soft-tissue sarcomas. WT1 may also serve as a potential therapeutic target. Coosemans et al. studied the role of WT1 and found WT1 positivity was seen in 12/27 carcinosarcoma, 29/38 leiomyosarcoma, 7/15 endodermal stromal tumor, and 4/7 undifferentiated sarcoma. They concluded that WT1 is overexpressed in uterine sarcomas.[8] Molecular testing can be helpful in cases where morphology alone is not confirmatory. The molecular alterations include ATRX, TP53, CDKN2A, and PTEN.[9]

These are highly metastatic malignancies with 5-year overall survival varying between 0% and 73%.[4] FIGO stage is the most important deciding feature of recurrence-free, overall, and disease-free survival in patients. Other prognosis factors such as age, race, tumor grade, size of the tumor, mitotic count, and lymphovascular invasion.[3] Uterine leiomyosarcoma has a strong metastatic potential to distant sites even many years after hysterectomy. The most common sites of distal metastases are the lungs, followed by the liver.[5] Metastases to the kidney, brain, bones, heart, thyroid, parotid gland, and oral cavity have also been reported.[1] Ours is a case of lymph node metastases. Surgery is the treatment of choice, but the patient should be closely followed up for recurrences and metastasis. Since it is a highly aggressive tumor and can metastasize to various organs, a proper diagnosis, management, and follow-up of the patient

   Conclusion Top

Uterine epithelioid leiomyosarcoma is a very rare and aggressive sarcoma of the uterus. It is difficult to diagnose on microscopy alone at times and a panel of IHCS especially the additional IHCs such as WT1, P53, CD117, and p16 are helpful where molecular investigations are not feasible. WT1 has diagnostic as well as prognostic importance. Surgery is the treatment of choice, but the patient should be followed up for recurrences or metastasis.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

Lin CH, Yeh CN, Chen MF. Breast metastasis from uterine leiomyosarcoma: A case report. Arch Gynecol Obstet 2003;267:233-5.  Back to cited text no. 1
International Agency for Research on Cancer. World Health Organization Classification of Tumours of the Female Reproductive Organs. 5th ed. Lyon: International Agency for Research on Cancer; 2020.  Back to cited text no. 2
Chapel DB, Nucci MR, Quade BJ, Parra-Herran C. Epithelioid leiomyosarcoma of the uterus: Modern outcome-based appraisal of diagnostic criteria in a large institutional series. Am J Surg Pathol 2022;46:464-75.  Back to cited text no. 3
Setia A, Kanotra S, Aggarwal R, Bhavthankar DP. Epithelioid leiomyosarcoma of uterus. BMJ Case Rep 2012;2012:bcr1120115144.  Back to cited text no. 4
Gallup DG, Cordray DR. Leiomyosarcoma of the uterus: Case reports and a review. Obstet Gynecol Surv 1979;34:300-12.  Back to cited text no. 5
Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54:355-64.  Back to cited text no. 6
del Carmen MG. Uterine leiomyosarcoma. In: del Carmen MG, Young RH, Schorge JO, Birrer MJ, eds. Uncommon Gynecologic Cancers; 2014. doi:10.1002/9781118655344.ch15.  Back to cited text no. 7
Coosemans A, Nik SA, Caluwaerts S, Lambin S, Verbist G, Van Bree R, et al. Upregulation of Wilms’ tumour gene 1 (WT1) in uterine sarcomas. Eur J Cancer 2007;43:1630-7.  Back to cited text no. 8
Astolfi A, Nannini M, Indio V, Schipani A, Rizzo A, Perrone AM, et al. Genomic database analysis of uterine leiomyosarcoma mutational profile. Cancers (Basel) 2020;12: E2126.  Back to cited text no. 9


  [Figure 1], [Figure 2], [Figure 3]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
   Case Report
    Article Figures

 Article Access Statistics
    PDF Downloaded14    
    Comments [Add]    

Recommend this journal